Serruya, Delavaco join Scythian Biosciences' $14.4 mln offering
Toronto-based pharmaceutical company Scythian Biosciences Corp (TSX-V: SCYB) has increased the size of its bought deal offering to about $14.4 million, including the greenshoe option. Additional investors, including Canadian family office Serruya Private Equity and Canadian private equity firm Delavaco Group, will contribute. The company is raising a comparable amount from Canadian medical cannabis producer Aphria Inc. Scythian is focused on developing a cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury. It intends to use the deal's proceeds for working capital and other priorities.
17 January 2018•4 mins read
